Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Inoperable estrogen receptor positive, Her-2 negative advanced breast cancer
Previously treated with an aromatase inhibitor
Primary or secondary hormone resistance
Acceptable glucose control, bone marrow, liver and kidney function
You may not be if
Inflammatory breast carcinoma
Prior therapy with an agent active on PI3K, Akt, and/or mTOR
Known hypersensitivity to exemestane
Significant gastrointestinal abnormalities which may impair intake, transit, or absorption of the study drugs
Current or anticipated need for food or drugs that are known inhibitors or inducers of CYP3A4
Clareo Health | Study Of PF-04691502 (PI3K/mTOR Inhibitor) In Combination With Exemestane Compared With Exemestane Alone In Patients With Advanced Breast Cancer
